Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0298269 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Xiaobin Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi Medical Center, Department of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi,…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Ricin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Social Development Fund of Zhejiang Province, Chinese National Natural Science Foundation, Key Research and Development Project of Zhejiang Province.
Abstract (Originalsprache)
Background
M-type phospholipase A2 receptor (PLA2R) is the major autoantigen in adult idiopathic membranous nephropathy (IMN). Although reactive epitopes in the PLA2R domains have been identified, the clinical value of these domains recognized by anti-PLA2R antibodies remains controversial. Accordingly, this study aimed to quantitatively detect changes in the concentrations of different antibodies against epitopes of PLA2R in patients with IMN before and after treatment to evaluate the clinical value of epitope spreading.
Methods
Highly sensitive time-resolved fluorescence immunoassay was used to quantitatively analyze the concentrations of specific IgG and IgG4 antibodies against PLA2R and its epitopes (CysR, CTLD1, CTLD6-7-8) in a cohort of 25 patients with PLA2R-associated membranous nephropathy (13 and 12 in the remission and non-remission groups, respectively) before and after treatment, and the results were analyzed in conjunction with clinical biochemical indicators.
Results
The concentration of specific IgG (IgG4) antibodies against PLA2R and its epitopes (CysR, CTLD1 and CTLD6-7-8) in non-remission group was higher than that in remission group. The multipliers of elevation of IgG (IgG4) antibody were 5.6(6.2) fold, 3.0(24.3) fold, 1.6(9.0) fold, and 4.2(2.6) fold in the non-remission/remission group, respectively. However, the difference in antibody concentrations between the two groups at the end of follow-up was 5.6 (85.2), 1.7 (13.1), 1.0 (5.1), and 1.5 (22.3) times higher, respectively. When detecting concentrations of specific IgG antibodies against PLA2R and its different epitopes, the remission rate was 66.67% for only one epitope at M0 and 36.36% for three epitopes at M0. When detecting concentrations of specific IgG4 antibodies against PLA2R and its different epitopes, the remission rate was 100.00% for only one epitope at M0 and 50.00% for three epitopes at M0. A trivariate logistic regression model for the combined detection of eGFR, anti-CTLD678 IgG4, and urinary protein had an AUC of 100.00%.
Conclusion
Low concentrations of anti-CysR-IgG4, anti-CTLD1-IgG4, and anti-CTLD6-7-8-IgG4 at initial diagnosis predict rapid remission after treatment. The use of specific IgG4 against PLA2R and its different epitopes combined with eGFR and urinary protein provides a better assessment of the prognostic outcome of IMN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wuxi Medical Center, Department of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
- Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Wuxi Children's Hospital, Wuxi, China.
- Zhejiang Provincial People's Hospital, Hangzhou, China.
- School of Life Science, Westlake University, Hangzhou, China.
ORCID-Profile: Liang Wang
Förderung
- Social Development Fund of Zhejiang Province
- Chinese National Natural Science Foundation
- Key Research and Development Project of Zhejiang Province
- the Natural Science Foundation of Zhejiang Province
- Key Research and Development Project of Hangzhou
- Precision medicine key project of Wuxi Health Commission
- the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee
- Wuxi Medical Innovation Team Project
Zitieren
APA
Liu, X., Xue, J., Li, T., Wu, Q., Sheng, H., Yang, X., Lin, B., Zhou, X., Qin, Y., Huang, Z., Zhou, L., Wang, L., Hu, Z., & Huang, B. (2024). Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy. PLOS ONE. https://doi.org/10.1371/journal.pone.0298269
Vancouver
Liu X, Xue J, Li T, Wu Q, Sheng H, Yang X, et al. Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy. PLOS ONE. 2024. doi:10.1371/journal.pone.0298269
BibTeX
@article{Liu2024,
author = {Liu, Xiaobin and Xue, Jing and Li, Ting and Wu, Qingqing and Sheng, Huiming and Yang, Xue and Lin, Bo and Zhou, Xiumei and Qin, Yuan and Huang, Zijian and Zhou, Leting and Wang, Liang and Hu, Zhigang and Huang, Biao},
title = {Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0298269}
}
EUVIMED